论文部分内容阅读
目的探讨参麦注射液联合尿激酶溶栓治疗急性下壁心肌梗死患者的疗效及对其心功能相关指标的影响。方法选择72例急性下壁心肌梗死患者,根据入院先后顺序分为研究组(n=36)与对照组(n=36)。对照组采用常规西医治疗措施(阿司匹林、吗啡注射液、尿激酶),研究组在对照组用药基础上加用参麦注射液。对比治疗前后两组相关酶指标[丙二醛(MDA)、超氧化物歧化酶(SOD)、脑钠肽(BNP)、肌酸激酶同工酶(CK-MB)、缺血修饰性蛋白(IMA)]水平变化情况、心功能各指标(射血分数、左室舒张末内径)水平及预后效果。结果治疗前两组MDA、SOD、BNP、CK-MB、IMA水平对比差异无统计学意义(P>0.05),经治疗,研究组MDA、SOD、BNP水平明显优于对照组,差异有统计学意义(P<0.05);两组射血分数、左室舒张末内径对比,差异无统计学意义(P>0.05);两组休克及病死率对比,差异无统计学意义(P>0.05);研究组心绞痛、心力衰竭发生率明显低于对照组,差异有统计学意义(P<0.05)。结论在尿激酶溶栓治疗基础上采用参麦注射液治疗急性下壁心肌梗死患者效果显著,可有效改善其心功能及相关酶指标水平,提高预后效果,具有推广价值。
Objective To investigate the effect of Shenmai injection combined with urokinase thrombolysis on patients with acute inferior myocardial infarction and its influence on the cardiac function related indexes. Methods Seventy-two patients with acute inferior myocardial infarction were divided into study group (n = 36) and control group (n = 36) according to the order of admission. The control group using conventional Western medicine treatment (aspirin, morphine injection, urokinase), the study group in the control group based on the use of Shenmai injection. Before and after treatment, the levels of malondialdehyde (MDA), superoxide dismutase (SOD), brain natriuretic peptide (BNP), creatine kinase isoenzyme (CK-MB) IMA)] levels, cardiac function (ejection fraction, left ventricular end-diastolic diameter) and prognosis. Results There was no significant difference in the levels of MDA, SOD, BNP, CK-MB and IMA between the two groups before treatment (P> 0.05). After treatment, the levels of MDA, SOD and BNP in the study group were significantly better than those in the control group (P <0.05). There was no significant difference in ejection fraction and left ventricular end diastolic diameter between the two groups (P> 0.05). There was no significant difference in shock and mortality between the two groups (P> 0.05). The study group angina pectoris, heart failure incidence was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion The treatment of acute inferior myocardial infarction with shenmai injection on the basis of urokinase thrombolytic therapy has significant effect, which can effectively improve the level of cardiac function and related enzymes and improve the prognosis, and has the value of popularization.